Unity CEO Anirvan Ghosh, Ph.D./courtesy of Unity Biotechnology

Senolytic therapies are, at this point, as revolutionary as checkpoint inhibitors but with broader effectiveness. This approach delays the onset of diseases of aging by removing senescent cells from the body, thus enabling people to remain healthier longer or to regain some degree of function lost to disease.

Senolytics is a new field and most of the research is still in academic centers – most notably, the Mayo Clinic. Approval of any therapeutics is years – perhaps even a decade – away.

During aging, mice, like humans, become inactive and lose muscle mass and strength. A team of scientists led by Johan Auwerx at EPFL have now discovered that when mice age, their muscles become packed with ceramides. Ceramides, known for their use in skin care products, are sphingolipids, a class of fat molecules that are not used to produce energy but rather perform different tasks in the cell.

The researchers found that, in aging, there is an overload of the protein SPT and others, all of which are needed to convert fatty acids and amino acids to ceramides. “The sphingolipids and ceramides are complex yet very interesting fat class, and there is high potential to further study their role in aging, as they perform many diverse functions,” says Dr. Pirkka-Pekka Laurila, a medical doctor and the lead author of the study.

Next, the scientists wanted to see whether reducing ceramide overload could prevent age-related decline in muscle function. They treated old mice with ceramide blockers, such as myriocin and the synthetic blocker Takeda-2, and used adeno-associated viruses to block ceramide synthesis specifically in muscle. The ceramide blockers prevented loss of muscle mass during aging, made the mice stronger, and allowed them to run longer distances while improving their coordination.

In his lively tour of longevity science and pseudoscience, Ward, a British reporter, discovers that researchers are largely not as interested in immortality per se as much as in helping us live fulfilling, active lives until our final day. And while some immortalists hope the culmination of this effort will eventually lead us to never finding that day, Ward leaves the question open.

He begins at the Church of Perpetual Life, a congregation of people who, instead of seeking paradise after death, would rather avoid their demise altogether. There, Ward meets Neal VanDeRee, the church’s pastor, who practices intermittent fasting and envisions a future in which biotechnology advances faster than our bodies break down.

VanDeRee is working to reach what he and other immortalists call “escape velocity” by extending their lives until biotechnology progresses fast enough to keep them alive forever. Another immortalist, Aubrey de Grey, sees this moment as surprisingly close — within 20 to 30 years, or maybe even sooner. It’s quite a claim, but is it possible? “Either we’ll discover we can make people healthy for longer but our lifespan is quite set, as most gerontologists believe, or de Grey’s longevity escape velocity will be proven correct,” Ward writes, never quite telling us which future he is betting on.

San Diego based biotech Immunicom has developed an innovative therapeutic device that is intended to remove specific factors from blood that prevent our immune systems from fighting disease. Existing “therapeutic apheresis” treatments usually involve modification to cells harvested from patients or some form of plasma exchange. Immunicom’s technology uses a similar treatment procedure but says its approach of “capturing” targeted molecules is very different from other treatments.

Immunicom creates customised molecules that are designed to capture specific proteins or cytokines, but instead of turning those into drugs, it deploys them via its proprietary cartridges, which are essentially small liquid filters that can be fitted into any plasmapheresis machine. In a treatment similar to dialysis, the cartridges are used to treat a patient’s blood and plasma outside their body, reducing the levels of the target factors, with the goal of enabling the immune system to fight disease.

While Immunicom has focused its initial efforts on treatments for cancer, the company claims its technology can also potentially be applied to longevity and the treatment of a wide range of age-related diseases.

While scientists around the world pursue ways to extend the human healthspan, cancer cells have found a way to become immortal.

For the first time, researchers have discovered how one type of cancer – melanoma – achieves that immortality.

New video: Dr. Aaron Cravens, CEO of Revel Pharmaceuticals at #RejuvenationStartupSummit 2022 about developing designer enzymes to treat diseases of aging, e.g. glucosepane crosslink breakers to prevent hardening of tissues such as muscle, skin, and arteries leading to increased blood pressure, vascular damage, and wrinkling of the skin.

Enjoy →

For more summit videos and regular updates, visit: youtube.com/user/foreverhealthyorg

Aaron Cravens, CEO of Revel Pharmaceuticals at Rejuvenation Startup Summit 2022.

Connect to Forever Healthy: